Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 4, Issue 10
May 26 2020
Issue Cover

Table of Contents

CLINICAL GUIDELINES

Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences
Wojtek Wiercioch,Robby Nieuwlaat,Elie A. Akl,Robert Kunkle,Kendall E. Alexander,Adam Cuker,Anita Rajasekhar,Pablo Alonso-Coello,David R. Anderson,Shannon M. Bates,Mary Cushman,Philipp Dahm,Gordon Guyatt,Alfonso Iorio,Wendy Lim,Gary H. Lyman,Saskia Middeldorp,Paul Monagle,Reem A. Mustafa,Ignacio Neumann,Thomas L. Ortel,Bram Rochwerg,Nancy Santesso,Sara K. Vesely,Daniel M. Witt,Holger J. Schünemann
View Articletitled, Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences
Supplemental data

EXCEPTIONAL CASE REPORT

Bilateral retinal detachment after chimeric antigen receptor T-cell therapy
Clinical Trials & Observations
Christopher C. Denton,William S. Gange,Hisham Abdel-Azim,Sonata Jodele,Neena Kapoor,Matthew J. Oberley,Kenneth Wong,Jonathan Kim,Abby Vercio,Parisah Moghaddampour,K. V. Chalam,David Sierpina,Rebecca A. Gardner,Michael A. Pulsipher,Michael C. Jensen,Aaron Nagiel
View Articletitled, Bilateral retinal detachment after chimeric antigen receptor T-cell therapy
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial
Clinical Trials & Observations
Jeffrey I. Zwicker,Joanna Roopkumar,Maneka Puligandla,Benjamin L. Schlechter,Anish V. Sharda,David Peereboom,Robin Joyce,Bruno Bockorny,Donna Neuberg,Kenneth A. Bauer,Alok A. Khorana
View Articletitled, Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Clinical Trials & Observations
Talha Badar,Aniko Szabo,Anjali Advani,Martha Wadleigh,Shukaib Arslan,Muhammad Ali Khan,Ibrahim Aldoss,Caitlin Siebenaller,Elizabeth Schultz,Mehrdad Hefazi,Rory M. Shallis,Ilana Yurkiewicz,Nikolai Podoltsev,Anand A. Patel,Emily Curran,Suresh Balasubramanian,Jay Yang,Ryan J. Mattison,Madelyn Burkart,Shira Dinner,Michaela Liedtke,Mark R. Litzow,Ehab Atallah
View Articletitled, Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
Alak Manna,Timothy Kellett,Sonikpreet Aulakh,Laura J. Lewis-Tuffin,Navnita Dutta,Keith Knutson,Eduardo Chini,Javier Pinilla-Ibarz,Nicole Lamanna,Rami Manochakian,Fabio Malavasi,Taimur Sher,Asher A. Chanan-Khan,Sikander Ailawadhi,Aneel Paulus
View Articletitled, Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8<sup>+</sup> T-cell responses
Supplemental data
Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma
Masato Saito,Toshihiko Ishii,Itaru Urakawa,Asuka Matsumoto,Ayako Masaki,Asahi Ito,Shigeru Kusumoto,Susumu Suzuki,Takeshi Takahashi,Akimichi Morita,Hiroshi Inagaki,Shinsuke Iida,Takashi Ishida
View Articletitled, Robust CD8<sup>+</sup> T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma
Supplemental data
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules
Chiara Barberi,Claudia De Pasquale,Alessandro Allegra,Giacomo Sidoti Migliore,Daniela Oliveri,Fabrizio Loiacono,Vanessa Innao,Caterina Musolino,Daniela Pende,Claudia Cantoni,Paolo Carrega,Maria Cristina Mingari,Stefania Campana,Guido Ferlazzo
View Articletitled, Myeloma cells induce the accumulation of activated CD94<sup>low</sup> NK cells by cell-to-cell contacts involving CD56 molecules
Supplemental data
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Clinical Trials & Observations
Xian Zhang,Xin-an Lu,Junfang Yang,Gailing Zhang,Jingjing Li,Lisong Song,Yunchao Su,Yanze Shi,Min Zhang,Jiujiang He,Dan Song,Fanyong Lv,Wenqian Li,Yan Wu,Hui Wang,Hongxing Liu,Xiaosu Zhou,Ting He,Peihua Lu
View Articletitled, Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Supplemental data

LYMPHOID NEOPLASIA

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Clinical Trials & Observations
Rafael Alonso,María-Teresa Cedena,Sandy Wong,Nina Shah,Rafael Ríos-Tamayo,José M. Moraleda,Javier López-Jiménez,Cristina García,Natasha Bahri,Antonio Valeri,Ricardo Sánchez,Luis Collado-Yurrita,Thomas Martin,Jeffrey Wolf,Juan-José Lahuerta,Joaquín Martínez-López
View Articletitled, Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Search for multiple myeloma risk factors using Mendelian randomization
Molly Went,Alex J. Cornish,Philip J. Law,Ben Kinnersley,Mark van Duin,Niels Weinhold,Asta Försti,Markus Hansson,Pieter Sonneveld,Hartmut Goldschmidt,Gareth J. Morgan,Kari Hemminki,Björn Nilsson,Martin Kaiser,Richard S. Houlston
View Articletitled, Search for multiple myeloma risk factors using Mendelian randomization
Supplemental data
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Sara Yumeen,Fatima N. Mirza,Julia M. Lewis,Amber Loren O. King,Sa Rang Kim,Kacie R. Carlson,Sheila R. Umlauf,Yulia V. Surovtseva,Francine M. Foss,Michael Girardi
View Articletitled, JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Supplemental data
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
Patrick W. Mellors,Moritz Binder,Rhett P. Ketterling,Patricia T. Greipp,Linda B. Baughn,Jess F. Peterson,Dragan Jevremovic,Kathryn E. Pearce,Francis K. Buadi,Martha Q. Lacy,Morie A. Gertz,Angela Dispenzieri,Suzanne R. Hayman,Prashant Kapoor,Wilson I. Gonsalves,Yi L. Hwa,Amie Fonder,Miriam Hobbs,Taxiarchis Kourelis,Rahma Warsame,John A. Lust,Nelson Leung,Ronald S. Go,Robert A. Kyle,S. Vincent Rajkumar,Shaji K. Kumar
View Articletitled, Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
Supplemental data
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Clinical Trials & Observations
Smith Giri,Scott F. Huntington,Rong Wang,Amer M. Zeidan,Nikolai Podoltsev,Steven D. Gore,Xiaomei Ma,Cary P. Gross,Amy J. Davidoff,Natalia Neparidze
View Articletitled, Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms
Natasha E. Lewis,Kseniya Petrova-Drus,Sarah Huet,Zachary D. Epstein-Peterson,Qi Gao,Allison E. Sigler,Jeeyeon Baik,Neval Ozkaya,Alison J. Moskowitz,Anita Kumar,Steven M. Horwitz,Yanming Zhang,Maria E. Arcila,Ross L. Levine,Mikhail Roshal,Ahmet Dogan,Wenbin Xiao
View Articletitled, Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms
Supplemental data
High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma
Clinical Trials & Observations
Hajime Senjo,Kenji Hirata,Koh Izumiyama,Koichiro Minauchi,Eriko Tsukamoto,Kazuo Itoh,Minoru Kanaya,Akio Mori,Shuichi Ota,Daigo Hashimoto,Takanori Teshima,North Japan Hematology Study Group
View Articletitled, High metabolic heterogeneity on baseline <sup>18</sup>FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma
Supplemental data

MYELOID NEOPLASIA

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Clinical Trials & Observations
Amer M. Zeidan,Rong Wang,Xiaoyi Wang,Rory M. Shallis,Nikolai A. Podoltsev,Jan P. Bewersdorf,Scott F. Huntington,Natalia Neparidze,Smith Giri,Steven D. Gore,Amy J. Davidoff,Xiaomei Ma
View Articletitled, Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Supplemental data
Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia
Clinical Trials & Observations
Douglas R. A. Silveira,Lynn Quek,Itamar S. Santos,Anna Corby,Juan L. Coelho-Silva,Diego A. Pereira-Martins,Grant Vallance,Benjamin Brown,Luciana Nardinelli,Wellington F. Silva,Elvira D. R. P. Velloso,Antonio R. Lucena-Araujo,Fabiola Traina,Andy Peniket,Paresh Vyas,Eduardo M. Rego,Israel Bendit,Vanderson Rocha
View Articletitled, Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia
Supplemental data

PLATELETS AND THROMBOPOIESIS

Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1
Isabelle C. Becker,Inga Scheller,Lou M. Wackerbarth,Sarah Beck,Tobias Heib,Katja Aurbach,Georgi Manukjan,Carina Gross,Markus Spindler,Zoltan Nagy,Walter Witke,Pekka Lappalainen,Markus Bender,Harald Schulze,Irina Pleines,Bernhard Nieswandt
View Articletitled, Actin/microtubule crosstalk during platelet biogenesis in mice is critically regulated by Twinfilin1 and Cofilin1
Supplemental data

THROMBOSIS AND HEMOSTASIS

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry
Clinical Trials & Observations
Zara Sayar,Anna Weatherill,Stephen Keddie,Jonathan Sive,Michael P. Lunn,Mari Thomas,Shirley D’Sa
View Articletitled, High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry
Supplemental data
Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy
Shuang Li,Shixuan Liu,Xiaoran Roger Liu,Mengru Mira Zhang,Weikai Li
View Articletitled, Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy
Supplemental data
Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice
Qizhen Shi,Christopher V. Carman,Yingyu Chen,Peter T. Sage,Feng Xue,Xin M. Liang,Gary E. Gilbert
View Articletitled, Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice
Supplemental data

TRANSPLANTATION

Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant
Clinical Trials & Observations
Prashant Sharma,Enkhtsetseg Purev,Bradley Haverkos,Daniel A. Pollyea,Evan Cherry,Manali Kamdar,Tomer Mark,Peter Forsberg,Daniel Sherbenou,Andrew Hammes,Rachel Rabinovitch,Clayton A. Smith,Jonathan A. Gutman
View Articletitled, Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant
Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality
Clinical Trials & Observations
Celalettin Ustun,Todd E. DeFor,Fatma K. Karadag,Hyun Don Yun,Sunita Nathan,Claudio G. Brunstein,Bruce R. Blazar,Daniel J. Weisdorf,Shernan G. Holtan,Khalid Amin
View Articletitled, Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality

COMMENTARIES

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome
Clinical Trials & Observations
Nirav N. Shah,Bryon D. Johnson,Timothy S. Fenske,Renju V. Raj,Parameswaran Hari
View Articletitled, Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome
Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia
Clinical Trials & Observations
Thibault Comont,Johanne Germain,Odile Beyne-Rauzy,Daniel Adoue,Guillaume Moulis,and the CARMEN investigators group
View Articletitled, Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia

ERRATA

Shamay M, Kanakry JA, Low JSW, et al. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. Blood Adv. 2020;4(8):1624-1627.
View Articletitled, Shamay M, Kanakry JA, Low JSW, et al. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. <em>Blood Adv.</em> 2020;4(8):1624-1627.
Ceriani L, Gritti G, Cascione L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020;4(6):1082-1092.
View Articletitled, Ceriani L, Gritti G, Cascione L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <em>Blood Adv.</em> 2020;4(6):1082-1092.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Confocal fluorescence microscopic image of a femur cryosection of a twinfilin-1/cofilin-1–deficient mouse displaying an increased amount of megakaryocytes, which is visualized by platelet glycoprotein IX staining (green). CD105 staining (red) labels vessels, and DAPI (4′,6-diamidino-2-phenylindole) counterstaining (blue) indicates nuclei. See the article by Becker et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals